candesartan has been researched along with Retinal Degeneration in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Retinal Degeneration: A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Narimatsu, T | 1 |
| Ozawa, Y | 1 |
| Miyake, S | 1 |
| Nagai, N | 1 |
| Tsubota, K | 1 |
1 other study available for candesartan and Retinal Degeneration
| Article | Year |
|---|---|
Angiotensin II type 1 receptor blockade suppresses light-induced neural damage in the mouse retina.
Topics: Acetylcysteine; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Apoptosis; Benzimida | 2014 |